MITOXANTRONE Side Effects

5232282-0 | Acute Promyelocytic Leukaemia, Anaemia, Hepatomegaly, Leukopenia, Pallor, Thrombocytopenia
on Jan 23, 2007 Female patient from ITALY , 37 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: acute promyelocytic leukaemia, anaemia, hepatomegaly, leukopenia, pallor, thrombocytopenia. Mitoxantrone dosage: . During the same period patient was treated with CORTICOSTEROIDS (View Corticosteroids Review and Corticosteroids Label ), INTERFERON BETA (View Interferon Beta Review and Interferon Beta Label ).

5219117-7 | Lung Adenocarcinoma
Patient was taking Mitoxantrone (View Usage). Patient had the following side effects: lung adenocarcinoma on Jan 24, 2007 from UNITED STATES Additional patient health information: Female patient , 64 years of age, weighting 168.0 lb, . Mitoxantrone dosage: 22 Mg X3 Every Months Iv. Patient was hospitalized.

5218957-8 | Asthenia, B-cell Lymphoma Stage Iv, Diabetes Mellitus, Follicle Centre Lymphoma Diffuse Small Cell Lymphoma, Haemoglobin Decreased, Pyrexia, Weight Decreased
Adverse event was reported on Jan 12, 2007 by a Female patient taking Mitoxantrone (View Usage) (Dosage: 8mg/m2, Day 2 Only, Iv) . Location: UNITED STATES , weighting 116.0 lb, After Mitoxantrone was administered, patient had the following side effects: asthenia, b-cell lymphoma stage iv, diabetes mellitus, follicle centre lymphoma diffuse small cell lymphoma, haemoglobin decreased, pyrexia, weight decreased. During the same period patient was treated with IRON (View Iron Review and Iron Label ), PROCRIT (View Procrit Review and Procrit Label ), RED BLOOD CELLS (View Red Blood Cells Review and Red Blood Cells Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ), OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ). Patient was hospitalized.

5160875-8 | Acute Myeloid Leukaemia, Nuclear Magnetic Resonance Imaging Abnormal, Spinal Disorder, Stem Cell Transplant, Treatment Related Secondary Malignancy
on Nov 08, 2006 Female patient from ITALY , 35 years of age, was diagnosed with relapsing-remitting multiple sclerosis and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, nuclear magnetic resonance imaging abnormal, spinal disorder, stem cell transplant, treatment related secondary malignancy. Mitoxantrone dosage: Intravenous. Patient was hospitalized.


5158983-0 | Abdominal Pain, Acute Myeloid Leukaemia, Blood Bilirubin Increased, Chromosome Analysis Abnormal, Febrile Neutropenia, Hypotension, Hypoxia, Lung Infiltration, Multi-organ Failure
on Nov 06, 2006 Male patient from UNITED STATES , 64 years of age, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Mitoxantrone (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), acute myeloid leukaemia, blood bilirubin increased, chromosome analysis abnormal, febrile neutropenia, hypotension, hypoxia, lung infiltration, multi-organ failure. Mitoxantrone dosage: 12 Mg/m2 Q3w. During the same period patient was treated with PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), GOSERELIN (View Goserelin Review and Goserelin Label ), BICALUTAMIDE (View Bicalutamide Review and Bicalutamide Label ).

5143520-7 | Myelodysplastic Syndrome, Pneumonia
Patient was taking Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: myelodysplastic syndrome, pneumonia (What is pneumonia?) on Nov 01, 2006 from UNITED STATES Additional patient health information: Female patient , 59 years of age, was diagnosed with secondary progressive multiple sclerosis and. Mitoxantrone dosage: 12 Mg/m2 Every 3 Months Iv Drip. During the same period patient was treated with TYLENOL (View Tylenol Review and Tylenol Label ), POTASSIUM ACETATE (View Potassium Acetate Review and Potassium Acetate Label ), RESTORIL (View Restoril Review and Restoril Label ), LASIX (View Lasix Review and Lasix Label ).

5140962-0 | Atelectasis, Neutropenia, Pulmonary Embolism, Urinary Tract Infection
Adverse event was reported on Oct 27, 2006 by a Female patient taking Mitoxantrone (View Usage) (Dosage: 20 Mg Q 3 Month I.v.) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 46 years of age, weighting 140.0 lb, Patient experienced the following unwanted or unexpected effects: atelectasis, neutropenia, pulmonary embolism (What is pulmonary embolism?), urinary tract infection (What is urinary tract infection?). Patient was hospitalized.

5126721-3 | Haematotoxicity
on Oct 11, 2006 Male patient from UNITED STATES , weighting 201.3 lb, was treated with Mitoxantrone (View Usage). Patient had the following side effects: haematotoxicity. Mitoxantrone dosage: 25 Mg. Patient was hospitalized.

5121843-5 | Electrocardiogram Qt Corrected Interval Prolonged
on Sep 19, 2006 Female patient from GERMANY , 42 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: electrocardiogram qt corrected interval prolonged. Mitoxantrone dosage: Intravenous.

5115568-X | Acute Promyelocytic Leukaemia
Patient was taking Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: acute promyelocytic leukaemia on Sep 12, 2006 from UNITED STATES Additional patient health information: Male patient , 58 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Mitoxantrone dosage: 12 Mg/m2 Oth.

5115567-8 | Acute Promyelocytic Leukaemia
Adverse event was reported on Sep 12, 2006 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 12 Mg/m2 Oth) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 58 years of age, Patient had the following side effects: acute promyelocytic leukaemia.

5115566-6 | Acute Myeloid Leukaemia
on Sep 12, 2006 Male patient from UNITED STATES , 41 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: acute myeloid leukaemia. Mitoxantrone dosage: 12 Mg/m2 Oth.

5100762-4 | Osteonecrosis, Steroid Withdrawal Syndrome
on Aug 22, 2006 Male patient from UNITED KINGDOM , 53 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: osteonecrosis (What is osteonecrosis?), steroid withdrawal syndrome. Mitoxantrone dosage: . During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), FLUDARA (View Fludara Review and Fludara Label ).

5096493-X | Acute Promyelocytic Leukaemia, Cerebral Haemorrhage, Condition Aggravated, Retinal Haemorrhage
Patient was taking Mitoxantrone (View Usage). Patient had the following side effects: acute promyelocytic leukaemia, cerebral haemorrhage, condition aggravated, retinal haemorrhage on Aug 17, 2006 from GERMANY Additional patient health information: Male patient , 61 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Mitoxantrone dosage: 11 Other. Patient was hospitalized and became disabled.

5094503-7 | Acute Myeloid Leukaemia, Dysplasia, Monocytosis
Adverse event was reported on Aug 17, 2006 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 12 Mg/m2 Oth) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 41 years of age, After Mitoxantrone was administered, patient had the following side effects: acute myeloid leukaemia, dysplasia, monocytosis.

5094500-1 | Acute Promyelocytic Leukaemia
on Aug 17, 2006 Male patient from UNITED STATES , 58 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: acute promyelocytic leukaemia. Mitoxantrone dosage: 12 Mg/m2 Oth.

5094498-6 | Acute Promyelocytic Leukaemia
on Aug 17, 2006 Male patient from UNITED STATES , 58 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). Patient had the following side effects: acute promyelocytic leukaemia. Mitoxantrone dosage: 12 Mg/m2 Oth.

5081951-4 | Condition Aggravated, Psoriasis
Patient was taking Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: condition aggravated, psoriasis on Jul 31, 2006 from GERMANY Additional patient health information: Male patient , 40 years of age, was diagnosed with progressive multiple sclerosis and. Mitoxantrone dosage: Intravenous; See Image.

5061445-2 | Febrile Neutropenia
Adverse event was reported on Jul 19, 2006 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 20 Mg Once) was diagnosed with neoplasm malignant and. Location: UNITED STATES , 66 years of age, Patient experienced the following unwanted or unexpected effects: febrile neutropenia. During the same period patient was treated with FLUDARABINE (50 Mg Qd) (View Fludarabine Review and Fludarabine Label ). Patient was hospitalized.

5053621-X | Fistula, Local Anaesthesia, Malignant Neoplasm Progression, Osteonecrosis, Purulent Discharge, Wound Debridement
on Jan 14, 2005 Female patient from GERMANY , 62 years of age, weighting 116.8 lb, was diagnosed with breast cancer metastatic, metastases to bone and was treated with Mitoxantrone (View Usage). Patient had the following side effects: fistula (What is fistula?), local anaesthesia, malignant neoplasm progression, osteonecrosis (What is osteonecrosis?), purulent discharge, wound debridement. Mitoxantrone dosage: 19.7 Mg, Unk. During the same period patient was treated with NAVELBINE (41 Mg, Unk) (View Navelbine Review and Navelbine Label ), MITOMYCIN (16 Mg, Unk) (View Mitomycin Review and Mitomycin Label ), SOLU DECORTIN H (100 Mg, Unk) (View Solu-decortin-h Review and Solu-decortin-h Label ), XELODA (3000 Mg, Unk) (View Xeloda Review and Xeloda Label ), FORTECORTIN (8 Mg, Unk) (View Fortecortin Review and Fortecortin Label ), AROMASIN (1 Df, Qd) (View Aromasin Review and Aromasin Label ), ZOMETA (4 Mg, Qmo) (View Zometa Review and Zometa Label ).

5050633-7 | Agranulocytosis, Bronchial Obstruction, Leukaemia Recurrent, Respiratory Distress, Stenotrophomonas Infection
on Jun 26, 2006 Male patient from FRANCE , 59 years of age, was diagnosed with acute myeloid leukaemia and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: agranulocytosis, bronchial obstruction, leukaemia recurrent, respiratory distress, stenotrophomonas infection. Mitoxantrone dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5031157-X | Osteonecrosis, Steroid Withdrawal Syndrome
Patient was taking Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: osteonecrosis (What is osteonecrosis?), steroid withdrawal syndrome on May 30, 2006 from UNITED KINGDOM Additional patient health information: Male patient , 53 years of age, was diagnosed with lymphoma (What is lymphoma?) and. Mitoxantrone dosage: . During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ).

5022371-8 | Acute Myeloid Leukaemia, Anaemia, Chromosome Abnormality, Haemorrhagic Disorder, Lung Disorder, Neutropenia, Septic Shock, Thrombocytopenia
Adverse event was reported on May 19, 2006 by a Female patient taking Mitoxantrone (View Usage) (Dosage: 20 Mg) was diagnosed with secondary progressive multiple sclerosis and. Location: FRANCE , 51 years of age, Patient had the following side effects: acute myeloid leukaemia, anaemia, chromosome abnormality, haemorrhagic disorder, lung disorder, neutropenia, septic shock, thrombocytopenia. During the same period patient was treated with AZATHIOPRINE (View Azathioprine Review and Azathioprine Label ), INTERFERON BETA (View Interferon Beta Review and Interferon Beta Label ).

5009855-3 | Acute Promyelocytic Leukaemia, Asthenia, Haemorrhage, Treatment Noncompliance, Vomiting
on May 11, 2006 Female patient from FRANCE , 40 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: acute promyelocytic leukaemia, asthenia, haemorrhage, treatment noncompliance, vomiting. Mitoxantrone dosage: 12 Mg/m2 Monthly.

4950530-9 | Acute Myeloid Leukaemia, Acute Respiratory Failure, Amenorrhoea, Asthenia, Dizziness, Haematoma, Haemorrhoids, Hypotension
on Mar 06, 2006 Female patient from UNITED STATES , 47 years of age, was diagnosed with secondary progressive multiple sclerosis and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, acute respiratory failure, amenorrhoea, asthenia, dizziness (What is dizziness?), haematoma, haemorrhoids, hypotension. Mitoxantrone dosage: 12 Mg/m2, Once. During the same period patient was treated with AVONEX (View Avonex Review and Avonex Label ). Patient was hospitalized.

4911222-5 | Acute Lymphocytic Leukaemia, Bronchopulmonary Aspergillosis, Haematoma, Immunosuppression
Patient was taking Mitoxantrone (View Usage). Patient had the following side effects: acute lymphocytic leukaemia, bronchopulmonary aspergillosis, haematoma, immunosuppression on Jan 27, 2006 from UNITED STATES Additional patient health information: Female patient , 26 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Mitoxantrone dosage: 12 Mg/m2, 1 In 1 Months, Intravenous (not Otherwise Specified), 12mg/m2, 1 In 3 Months, Intravenous. During the same period patient was treated with GLATIRAMER ACETATE (View Glatiramer Acetate Review and Glatiramer Acetate Label ). Patient was hospitalized.

4911099-8 | Cardiac Arrest, Cardiac Disorder, Dyspnoea, Oedema
Adverse event was reported on Jan 28, 2006 by a Female patient taking Mitoxantrone (View Usage) (Dosage: 23 Mg, 1 In 3 Months) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 34 years of age, weighting 165.3 lb, After Mitoxantrone was administered, patient had the following side effects: cardiac arrest (What is cardiac arrest?), cardiac disorder, dyspnoea, oedema. During the same period patient was treated with GLATIRAMER ACETATE (View Glatiramer Acetate Review and Glatiramer Acetate Label ). Patient was hospitalized.

4898593-3 | Faecal Incontinence, Haematochezia, Mucous Stools
on Jan 16, 2006 Female patient from GERMANY , 63 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: faecal incontinence, haematochezia, mucous stools. Mitoxantrone dosage: 12 Mg/m2. Patient was hospitalized.

4891838-5 | Bradycardia, Cardiotoxicity, Sepsis
on Jan 11, 2006 Female patient from TURKEY , 76 years of age, was diagnosed with acute myeloid leukaemia and was treated with Mitoxantrone (View Usage). Patient had the following side effects: bradycardia, cardiotoxicity, sepsis (What is sepsis?). Mitoxantrone dosage: 10 Mg/m2, 1 In 1 Days, Intravenous. During the same period patient was treated with CYTARABINE ARABINOSIDE (CYTARABINE) (100 Mg/m2, 1 In 12 Hr, Intravenous) (View Cytarabine Arabinoside (cytarabine) Review and Cytarabine Arabinoside (cytarabine) Label ).

4877364-8 | Aortic Valve Incompetence, Aortic Valve Stenosis, Cardiac Failure, Dilatation Atrial, Dilatation Ventricular, Mitral Valve Incompetence, Pulmonary Hypertension, Sinus Tachycardia, Tricuspid Valve Incompetence
Patient was taking Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: aortic valve incompetence, aortic valve stenosis, cardiac failure, dilatation atrial, dilatation ventricular, mitral valve incompetence, pulmonary hypertension (What is pulmonary hypertension?), sinus tachycardia, tricuspid valve incompetence on Dec 22, 2005 from Additional patient health information: Female patient , 56 years of age, was diagnosed with disease progression, multiple sclerosis (What is multiple sclerosis?) and. Mitoxantrone dosage: 12 Mg/m2, 6 In 6 Cycle, Intravenous (not Ohterwise Specified).

4866891-5 | Bedridden, Cardiac Failure, Chest Pain, Tricuspid Valve Incompetence
Adverse event was reported on Dec 10, 2005 by a Female patient taking Mitoxantrone (View Usage) (Dosage: 12 Mg/m2, Intravenous) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: BELGIUM , 51 years of age, Patient experienced the following unwanted or unexpected effects: bedridden, cardiac failure, chest pain (What is chest pain?), tricuspid valve incompetence. Patient was hospitalized.

4866887-3 | Cardiac Failure
on Dec 10, 2005 Male patient from BELGIUM , 39 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). Patient had the following side effects: cardiac failure. Mitoxantrone dosage: Intravenous. Patient was hospitalized.

4866886-1 | Cardiac Failure Congestive, Intracardiac Thrombus, Jugular Vein Thrombosis, Vena Cava Thrombosis
on Dec 09, 2005 Female patient from BELGIUM , 44 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: cardiac failure congestive, intracardiac thrombus, jugular vein thrombosis, vena cava thrombosis. Mitoxantrone dosage: See Image. Patient was hospitalized.

4848009-8 | Blood Iron Decreased, Bone Marrow Failure, Candidiasis, Hypoxia, Mucosal Inflammation, Neutropenia, Stomatitis, Weight Decreased
Patient was taking Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: blood iron decreased, bone marrow failure, candidiasis, hypoxia, mucosal inflammation, neutropenia, stomatitis, weight decreased on Nov 21, 2005 from UNITED STATES Additional patient health information: Male patient , 53 years of age, . Mitoxantrone dosage: 10 Mg/m2 Daily. During the same period patient was treated with VINCRISTINE (2 Mg Daily) (View Vincristine Review and Vincristine Label ), CYCLOPHOSPHAMIDE (750 Mg/m2 Daily) (View Cyclophosphamide Review and Cyclophosphamide Label ), PREDNISONE TAB (100 Mg Daily) (View Prednisone Tab Review and Prednisone Tab Label ), RITUXIMAB (375 Mg/m2 Daily) (View Rituximab Review and Rituximab Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ), ISOSORBIDE MONONITRATE (View Isosorbide Mononitrate Review and Isosorbide Mononitrate Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ).

4836178-5 | Febrile Neutropenia, Proteus Infection, Pseudomonas Infection, Sepsis
Adverse event was reported on Nov 21, 2005 by a Male patient taking Mitoxantrone (View Usage) (Dosage: 12mg/m^2 Q3 Weeks Iv) was diagnosed with prostate cancer metastatic and. Location: UNITED STATES , weighting 151.1 lb, Patient had the following side effects: febrile neutropenia, proteus infection, pseudomonas infection, sepsis (What is sepsis?). During the same period patient was treated with PREDNISONE (10mg Qd Po) (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

4835961-X | Caesarean Section, Pneumocystis Jiroveci Pneumonia, Premature Labour
on Nov 04, 2005 Female patient from JAPAN , 20 years of age, was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: caesarean section, pneumocystis jiroveci pneumonia, premature labour. Mitoxantrone dosage: Intravenous. During the same period patient was treated with IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), PREDNISOLONE /00016201/ (View Prednisolone /00016201/ Review and Prednisolone /00016201/ Label ), VINDESINE SULFATE (View Vindesine Sulfate Review and Vindesine Sulfate Label ). Patient was hospitalized.

4834886-3 | Dialysis, Dyspnoea, Gastrointestinal Haemorrhage, Hepatic Failure, Multi-organ Failure, Pulmonary Haemorrhage, Renal Failure Acute, Werner's Syndrome
on Oct 31, 2005 Male patient from UNITED STATES , 44 years of age, was diagnosed with myeloid leukaemia and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: dialysis (What is dialysis?), dyspnoea, gastrointestinal haemorrhage, hepatic failure, multi-organ failure, pulmonary haemorrhage, renal failure acute, werner's syndrome. Mitoxantrone dosage: 80 Mg/m2, 1 In 1 Days. During the same period patient was treated with CYTARABINE (3000 Mg/m2, 1 In 1 Days) (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (150 Mg/m2, 1 In 2 Days) (View Etoposide Review and Etoposide Label ).

4830628-6 | Pancytopenia, Pyrexia
Patient was taking Mitoxantrone (View Usage). Patient had the following side effects: pancytopenia, pyrexia on Oct 27, 2005 from FRANCE Additional patient health information: Female patient , 21 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Mitoxantrone dosage: 20 Mg 1 In 1 Cycle Intravenous. During the same period patient was treated with AMANTADINE HCL (View Amantadine Hcl Review and Amantadine Hcl Label ).

4825220-3 | Bacterial Sepsis
Adverse event was reported on Nov 01, 2005 by a Female patient taking Mitoxantrone (View Usage) (Dosage: 17.6 Mg, 1 In 1 Days, Intravenous) was diagnosed with acute myeloid leukaemia and. Location: GERMANY , 47 years of age, After Mitoxantrone was administered, patient had the following side effects: bacterial sepsis. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN (4.9 Mg, 1 In 1 Days, Intravenous) (View Gemtuzumab Ozogamicin Review and Gemtuzumab Ozogamicin Label ), CYTARABINE (8.8 Mg, 1 In 1 Days, Intravenous) (View Cytarabine Review and Cytarabine Label ), TRETINOIN (See Image) (View Tretinoin Review and Tretinoin Label ).

4822766-9 | Malignant Fibrous Histiocytoma
on Oct 21, 2005 Female patient from GERMANY , 52 years of age, weighting 209.4 lb, was diagnosed with secondary progressive multiple sclerosis and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: malignant fibrous histiocytoma. Mitoxantrone dosage: See Image, Intravenous. During the same period patient was treated with UBRETID (DISTIGMINE BROMIDE) (View Ubretid (distigmine Bromide) Review and Ubretid (distigmine Bromide) Label ), UROXATRAL (View Uroxatral Review and Uroxatral Label ). Patient was hospitalized.

4819843-5 | Autoimmune Hepatitis, Condition Aggravated, Hepatic Encephalopathy
on Oct 19, 2005 Female patient from GERMANY , 52 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). Patient had the following side effects: autoimmune hepatitis, condition aggravated, hepatic encephalopathy. Mitoxantrone dosage: 14 Mg, Once, Intravenous (not Otherwise Specified). Patient was hospitalized.

4816251-8 | Acute Myeloid Leukaemia, Lung Disorder, Septic Shock
Patient was taking Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: acute myeloid leukaemia, lung disorder, septic shock on Oct 13, 2005 from FRANCE Additional patient health information: Female patient , 51 years of age, was diagnosed with secondary progressive multiple sclerosis and. Mitoxantrone dosage: 20 Mg,. During the same period patient was treated with AZATHIOPRINE (View Azathioprine Review and Azathioprine Label ), INTERFERON BETA (INTERFERON BETA) (View Interferon Beta (interferon Beta) Review and Interferon Beta (interferon Beta) Label ).

4815174-8 | Malignant Fibrous Histiocytoma
Adverse event was reported on Oct 11, 2005 by a Female patient taking Mitoxantrone (View Usage) (Dosage: 1 In 3 Months, Intravenous) was diagnosed with secondary progressive multiple sclerosis and. Location: UNITED STATES , 52 years of age, Patient experienced the following unwanted or unexpected effects: malignant fibrous histiocytoma. During the same period patient was treated with UBRETID (DISTIGMINE BROMIDE) (View Ubretid (distigmine Bromide) Review and Ubretid (distigmine Bromide) Label ), UROXATRAL (View Uroxatral Review and Uroxatral Label ). Patient was hospitalized.

4807734-5 | Osteonecrosis
on Oct 05, 2005 Male patient from GERMANY , 47 years of age, was diagnosed with progressive multiple sclerosis and was treated with Mitoxantrone (View Usage). Patient had the following side effects: osteonecrosis (What is osteonecrosis?). Mitoxantrone dosage: 12 Mg/m2. During the same period patient was treated with CORTISONE (CORTISONE /00014601/) (Intravenous) (View Cortisone (cortisone /00014601/) Review and Cortisone (cortisone /00014601/) Label ). Patient was hospitalized and became disabled.

4807724-2 | Blister, Herpes Simplex, Leukopenia, Scratch, Skin Necrosis, Ulcer
on Oct 05, 2005 Female patient from GERMANY , 23 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: blister, herpes simplex (What is herpes simplex?), leukopenia, scratch, skin necrosis, ulcer (What is ulcer?). Mitoxantrone dosage: 7 Dosage Forms, Intravenous.

4805103-5 | Cardiomyopathy, Ejection Fraction Decreased, White Blood Cell Count Decreased
Patient was taking Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: cardiomyopathy (What is cardiomyopathy?), ejection fraction decreased, white blood cell count decreased on Sep 29, 2005 from GERMANY Additional patient health information: Male patient , 24 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Mitoxantrone dosage: 12 Mg/m2.

4798998-5 | Bone Giant Cell Tumour, Metastases To Lung, Synovial Sarcoma Metastatic
Adverse event was reported on Sep 22, 2005 by a Female patient taking Mitoxantrone (View Usage) (Dosage: See Image) was diagnosed with secondary progressive multiple sclerosis and. Location: GERMANY , 55 years of age, Patient had the following side effects: bone giant cell tumour, metastases to lung, synovial sarcoma metastatic. Patient was hospitalized.

4791202-3 | Acute Promyelocytic Leukaemia
on Jun 14, 2005 Female patient from FRANCE , 47 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Mitoxantrone (View Usage). After Mitoxantrone was administered, patient had the following side effects: acute promyelocytic leukaemia. Mitoxantrone dosage: 60 Mg/m2 Total. During the same period patient was treated with VINORELBINE (300 Mg/m2 Total) (View Vinorelbine Review and Vinorelbine Label ), TAMOXIFEN (View Tamoxifen Review and Tamoxifen Label ).

4790155-1 | Blood Bilirubin Increased
on Oct 05, 2005 Female patient from UNITED STATES , 53 years of age, weighting 104.7 lb, was diagnosed with acute myeloid leukaemia recurrent and was treated with Mitoxantrone (View Usage). Patient experienced the following unwanted or unexpected effects: blood bilirubin increased. Mitoxantrone dosage: 12 Mg Iv. During the same period patient was treated with ETOPOSIDE (145 Mg Iv) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

4785526-3 | Acute Promyelocytic Leukaemia
Patient was taking Mitoxantrone (View Usage). Patient had the following side effects: acute promyelocytic leukaemia on Jun 14, 2005 from FRANCE Additional patient health information: Female patient , 26 years of age, was diagnosed with breast cancer (What is breast cancer?) and. Mitoxantrone dosage: 210 Mg/m2 Total. During the same period patient was treated with VINORELBINE (490 Mg/m2 Total) (View Vinorelbine Review and Vinorelbine Label ).